Evidence map›Paper›PMID 41774065›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Multiparametric Bioresorbable Sensor for Doxorubicin Detection via Molecularly Imprinted Synthetic Receptors.

Martina Corsi, Tiziano Di Giulio, Eleonora Vandini, Muhammad Ibrar Asif, Eleonora Daini, Antonietta Vilella, Giuseppina Leo, Alessandra Ottani, Cosimino Malitesta, Daniela Giuliani and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martina CorsiDepartment of Information Engineering, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0001-6802-3100
Tiziano Di GiulioLaboratory of Analytical Chemistry, Department of Biological and Environmental Sciences and Technologies (Di.S.Te.B.A.), University of Salento, Lecce, Italy.ORCID https://orcid.org/0000-0003-3450-8980
Eleonora VandiniDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Muhammad Ibrar AsifLaboratory of Analytical Chemistry, Department of Biological and Environmental Sciences and Technologies (Di.S.Te.B.A.), University of Salento, Lecce, Italy.
Eleonora DainiDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Antonietta VilellaDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Giuseppina LeoDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Alessandra OttaniDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Cosimino MalitestaLaboratory of Analytical Chemistry, Department of Biological and Environmental Sciences and Technologies (Di.S.Te.B.A.), University of Salento, Lecce, Italy.
Daniela GiulianiDepartment of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Elisabetta MazzottaLaboratory of Analytical Chemistry, Department of Biological and Environmental Sciences and Technologies (Di.S.Te.B.A.), University of Salento, Lecce, Italy.ORCID https://orcid.org/0000-0003-1425-3116
Giuseppe BarillaroDepartment of Information Engineering, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0001-6197-4851

Funding

ForeLab project (Department of Excellence 2023-2027), funded by the Italian Ministry of University and ResearchRESORB Project, HORIZON EUROPE European Innovation Council 101046946
6 · The paper itself

Abstract

Monitoring chemotherapeutic drug concentrations directly at the tumor site remains a critical unmet need in oncology, as conventional pharmacokinetic assessments based on systemic circulation fail to capture the spatial and temporal heterogeneity of drug distribution within solid tumors. Here, we report a bioresorbable, multiparametric optical sensor designed for the in situ detection of the chemotherapeutic agent doxorubicin. The sensor integrates a nanostructured porous silica scaffold with a molecularly imprinted polymer (MIP) synthetic receptor that provides shape- and chemistry-selective recognition of doxorubicin molecules. Molecular binding events are transduced through two orthogonal optical signals: i) shifts in effective optical thickness and ii) fluorescence intensity changes, enabling accurate and self-validating quantification across clinically relevant concentration ranges. The sensor operates reliably in serum with a limit of detection as low as 0.1 µg/mL, and exhibits reversible performance with minimal signal drift (<15.3%) over 12 weeks -consistent with standard chemotherapy regimens. In vivo implantation studies in mice confirm biodegradation and biocompatibility, with no evidence of local or systemic toxicity. This platform introduces a versatile strategy for multiparametric, bioresorbable chemical sensing using MIP synthetic receptors, establishing a foundation for future implantable diagnostics in precision chemotherapy.

Indexed as

Antibiotics, AntineoplasticBiosensing TechniquesDoxorubicinMolecular ImprintingMolecularly Imprinted PolymersAnimalsHumansMiceAntibiotics, AntineoplasticDoxorubicinMolecularly Imprinted Polymersbioresorbable sensordoxorubicin monitoringimplantable diagnosticsmolecularly imprinted polymermultiparametric sensing

Identifiers

PMID41774065
PMCPMC13248826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.